LncRNA FAM83A-AS1 aggravates the malignant development of esophageal cancer by binding to miR-495-3p.
暂无分享,去创建一个
G-M Huang | Y. Geng | Hongliang Zang | Y-H Li
[1] Xing-ming Jiang,et al. Hypoxia and lncRNAs in gastrointestinal cancers. , 2019, Pathology, research and practice.
[2] I. Ulitsky,et al. Regulation of gene expression by cis-acting long non-coding RNAs , 2019, Nature Reviews Genetics.
[3] Shiming Yang,et al. Long non‐coding small nucleolar RNA host genes in digestive cancers , 2019, Cancer medicine.
[4] J. Lagergren,et al. Surgical and Surgeon-Related Factors Related to Long-Term Survival in Esophageal Cancer: A Review , 2019, Annals of Surgical Oncology.
[5] D. Chung,et al. Screening high‐risk populations for esophageal and gastric cancer , 2019, Journal of surgical oncology.
[6] A. Hadjinicolaou,et al. Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers , 2019, Medical sciences.
[7] A. Nimmo,et al. Identification of inflammatory mediators associated with metastasis of oral squamous cell carcinoma in experimental and clinical studies: systematic review , 2019, Clinical & Experimental Metastasis.
[8] Xin Sun,et al. FAM83A-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-150-5p and modifying MMP14 , 2019, Cell cycle.
[9] Min Su,et al. Involvement of noncoding RNAs in epigenetic modifications of esophageal cancer. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[10] Xitong Dang,et al. Potential functions of esophageal cancer-related gene-4 in the cardiovascular system , 2019, Frontiers of Medicine.
[11] J. Gong,et al. Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies. , 2019, Translational gastroenterology and hepatology.
[12] W. Yantasee,et al. siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion. , 2019, Translational research : the journal of laboratory and clinical medicine.
[13] A. Zaika,et al. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. , 2019, Biochimica et biophysica acta. Reviews on cancer.
[14] L. Qin,et al. Long noncoding RNAs, emerging and versatile regulators of tumor-induced angiogenesis. , 2019, American journal of cancer research.
[15] Hui Zhang,et al. Insight into long noncoding competing endogenous RNA networks in hepatic fibrosis: The potential implications for mechanism and therapy. , 2019, Gene.
[16] Tao Wang,et al. Long noncoding antisense RNA FAM83A‐AS1 promotes lung cancer cell progression by increasing FAM83A , 2019, Journal of cellular biochemistry.
[17] Sheng-Jie Yu,et al. Esophageal cancer: Risk factors, genetic association, and treatment. , 2016, Asian journal of surgery.
[18] N. Petrelli. Gastric and Esophageal Cancer 2017. , 2017, Surgical Oncology Clinics of North America.
[19] Y. Qiao,et al. Esophageal cancer in high-risk areas of China: research progress and challenges. , 2017, Annals of epidemiology.
[20] Tao Wu,et al. LncRNAs: From Basic Research to Medical Application , 2017, International journal of biological sciences.
[21] A. Morillon,et al. History, Discovery, and Classification of lncRNAs. , 2017, Advances in experimental medicine and biology.
[22] Xu Gao,et al. Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3 , 2016, Oncotarget.
[23] María José Domper Arnal,et al. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. , 2015, World journal of gastroenterology.
[24] Yingsong 櫻松 Lin 林,et al. Epidemiology of Esophageal Cancer in Japan and China , 2013, Journal of epidemiology.
[25] Peter D Siersema,et al. Esophageal cancer. , 2008, Gastroenterology clinics of North America.